Renin-Angiotensin System (RAS) Expressions in Myeloid Leukemic Cell Lines

Burak UZ1, Suzin C. TATONYAN2, Muge SAYITOGLU2, Yucel ERBILGIN2, Ozden HATIRNAZ NG2, Yahya BUYUKASIK1, Salih AKSU1, Nilgun SAYINALP1, Hakan GOKER1, Osman I. OZCEBE1, Ugur OZBEK2, Ibrahim C. HAZNEDAROGLU1

1 Hacettepe University Department of Internal Medicine, Hematology Unit, Ankara
2 Istanbul University Institute for Experimental Medicine Research, Genetics Department, Istanbul, TURKEY

ABSTRACT

The aim of this study is to search critical renin-angiotensin system (RAS) elements in myeloid leukemic cell lines. Human acute myeloid leukemia (AML) cell lines, KG-1 and HL-60, were cultured. We searched for the gene expression of the major RAS components in KG-1 and HL-60 cell lines by quantitative real-time polymerase chain reaction analysis (qRT-PCR). Angiotensin-converting enzyme I (ACE I) and ACE II mRNA expressions were detected in KG-1 AML cell line. Relative expression of ACE I was higher than ACE II expression in this myeloid leukemic cells. Likewise, RENIN, angiotensinogen (ANGTS), and ACE I mRNA expressions were detected in HL-60 promyelocytic cell line. Relative RENIN expression was the highest, whereas ACE I expression was the lowest in HL-60 neoplastic myeloid cells. These findings indicate that there is a biologically active local RAS in the hematopoietic system in normal and pathological states.

Keywords: Renin-angiotensin system, KG-1 AML cell line, HL-60 promyelocytic cell line, mRNA expressions

ÖZET

Miyeloid Lösemik Hücre Dizilerinde Renin-Anjiyotensin Sistem (RAS) Ekspresyonları

Bu çalışmanın amacı myeloid lösemik hücre dizilerinde kritik renin-anjiyotensin sistemi (RAS) elemanlarının varlığını araştırmaktır. İnsan akut myeloid lösemi (AML) hücre dizileri, KG-1 ve HL-60, kültüre edildi. Temel RAS elemanlarının KG-1 ve HL-60 hücre dizilerinde gen ekspresyon düzeyleri kuantitatif gerçek zamanlı polimeraz zincir reaksiyonu (qRT-PCR) ile araştırıldı. KG-1 AML hücre dizisinde anjiyotensin-dönüştürücü enzim I (ACE I) ve ACE II mRNA ekspresyonları saptandı; ACE I rölatif ekspresyonu, ACE II ekspresyonundan yüksekti. Benzer şekilde, HL-60 promyelositik hücre dizisinde RENIN, anjiyotensinojen (ANGTS) ve ACE I mRNA ekspresyonları saptandı; HL-60 neoplastik myeloid hücrelerinde rölatif RENIN ekspresyonu en yüksekti, ACE I ekspresyonu en düşük düzeyde bulundu. Bu bulgular hematopoetik sistemde normal ve patolojik durumlarda biyolojik aktif lokal bir RAS varlığını göstermektedir.

Anahtar Kelimeler: Renin-anjiyotensin sistemi, KG-1 AML hücre dizisi, HL-60 promiyelositik hücre dizisi, mRNA ekspresyonları
INTRODUCTION

There is a local renin-angiotensin system (RAS) in the hematopoietic bone marrow (BM). All of the RAS molecules such as renin, angiotensinogen (ANGTS), angiotensin receptors (AT1R and AT2R), AcSDKP and angiotensin-converting enzyme (ACE) are present in the BM microenvironment and cellular compartment. Local BM RAS acts in an autocrine, paracrine, and intracrine fashion affecting all of the cellular lineages. Local hematopoietic RAS is effective in the primitive embryonic hematopoiesis and neoplastic blood production.

Local BM RAS modulates myelopoiesis. Leukocytes express the angiotensinogen gene, synthesizing and releasing angiotensinogen with the capability to generate angiotensin (Ang). Prominent myelopoietic abnormalities characterized by increased BM myeloblasts and myeloid cells, as well as extramedullary myelopoiesis are present in the ACE (CD143)-knockout mice. Moreover, there are preliminary evidences that local BM RAS may be important in the pathobiology of myeloid leukemias. Casares et al. demonstrated that some myeloid blasts express renin, but normal BM does not display this expression. They observed renin expression in cells from acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and acute lymphoid leukemia (ALL). The highest frequency was observed in the AML patients (47.2% of the cases). Renin expression was disappeared during the complete remission of AML.

The aim of the present study is to search critical RAS elements in myeloid leukemic cell lines. For this aim, KG-1 AML and HL-60 promyelocytic cell lines were analyzed via the quantitative real-time polymerase chain reaction analysis (qRT-PCR). Elucidation of the status of the local RAS molecules in the leukemic hematopoiesis represents a clinically relevant basic research area for better understanding the biology of the diseases.

MATERIALS AND METHODS

Cell Culture, RNA Isolation and cDNA Synthesis

Human AML cell lines KG-1 (erythroleukemia cell line, spontaneously differentiate to granulocyte and macrophage like cells) and HL-60 (promyelocytic cell line) were cultured in RPMI 1640 (Invitrogen Life Technologies, USA), supplemented with 10% FCS, penicillin (50 U/mL), streptomycin (50 mg/mL; both Invitrogen Life Sciences, USA). Total ribonucleic acid (RNA) was isolated according to the manufacturer’s instructions (Qiagen, Germany). RNA quality was measured by spectrophotometer (ND-1000, Nanodrop Technologies, Inc., USA), and one microgram of total RNA was used. Random primers (20 µM, Roche Diagnostics, Germany), dNTP set 10 mM (Fermentase UAB, Lithuania), Ribolock Rnase Inhibitor (20 U/µl, Fermentas) and Moloney murine leukemia virus (MMLV) reverse transcriptase (200 U/µl, Fermentas) were used for cDNA synthesis. cDNA samples were stored at –20°C.

Quantitative real-time polymerase chain reaction analysis (qRT-PCR)

We searched for the gene expression of the major RAS components (ACE I, ACE II, RENIN and ANGTS) in KG-1 and HL-60 cell lines by qRT-PCR. Previously designed primer-probes were used. mRNA levels were normalized to CYPA and B-ACT genes. qRT-PCR analyses for ACE, RENIN and ANGTS gene expressions were performed using a LightCycler 480 instrument (Roche Diagnostics). Real-time amplification was performed with a final reaction mixture of 20 µl containing 5 µM of each primer, 0.5 µM of each probe and LightCycler 480 Probe Master Mix and 100 ng/µl of cDNA. Each sample was studied in duplicate and all runs were repeated twice. The PCR protocol was as follows: initial denaturation at 95°C for 7 min, amplification segment at 5 sec at 95°C, 10 sec at 60°C, and 10 sec at 72°C for 45 cycles. The 2–Ct method was used to calculate relative expression levels determined from the qRT-PCR experiments. Differences between two groups were assessed by the Mann-Whitney U test. A p value of ≤ .05 was considered as statistically significant.

RESULTS

KG-1 AML cell line and relative expressions of the RAS components

ACE I and ACE II mRNA expressions were detected. Relative expression of ACE I was higher than ACE II expression (p< 0.05) (Figure 1).
HL-60 promyelocytic cell line and relative expressions of the RAS components

RENIN, ANGTS, and ACE I mRNA expressions were detected. Relative RENIN expression was the highest, whereas ACE I expression was the lowest (p < 0.05) (Figure 1).

DISCUSSION

In this study, ACE I and ACE II mRNA expressions were detected in KG-1 AML cell line. Relative expression of ACE I was higher than ACE II expression in this myeloid leukemic cells. Likewise, RENIN, ANGTS, and ACE I mRNA expressions were detected in HL-60 promyelocytic cell line. Relative RENIN expression was the highest, whereas ACE I expression was the lowest in HL-60 neoplastic myeloid cells (Figure 1). These findings support our original hypothesis that there is a biologically active local RAS in the hematopoietic system in normal and pathological states.1,2,20

ACE existence in human primitive lympho-hematopoietic cells, embryonic, fetal and adult hematopoietic tissues cast attention to the effects of RAS on neoplastic tissues.6-7 Immunohistochemical studies showed the possible role of ACE/RAS in BM by evaluating ACE expression in normal BM, several myeloproliferative disorders and myelodysplasia.21 ACE and p53 expressions were detected in the CD34+ cells in the patients with acute leukemia during and after induction chemotherapy.21 In vitro incubation of AML cells with an ACE inhibitor decreased the growth and colony-forming ability of AML cells in a dose-dependent manner. Adding of Ang-II peptide to AML cells partially rescued their colony-forming ability.23 Over-expression of ACE (CD 143) surface antigen in leukemic myeloid blast cells have been detected by flow cytometric analyses. Moreover, a positive correlation has been found between the ACE and BM blast count.19 Our preliminary results regarding the ACE expressions in myeloid leukemic cells represent another clue for the actions of ACE in myeloid leukemogenesis.

RENIN expression was the highest in HL-60 myeloid leukemic cells in our study. The associations between renin and AML have previously been searched. The relevance of the renin expression as an aberrant leukemic marker in acute leukemia has been proposed by real-time PCR analyses. Renin-like enzyme activity converting ANGTS to Ang-I had been detected in leukemic blast cells.24,25 Specific immunoreactive renin-like peptide of 47 kDa was isolated from AML blast cells.24,25 Renin is expressed in some myeloid human leukemia cell lines such as K562, KU812 and MEG-01.9,18,26 Renin system is present in the K562 leukemic cell line in vitro model. Multipotential, hematopoietic malignant K562 leukemic blast cells also exhibited significant expressions of the renin, ANGTS and ACE.9 When K562 cells were treated with inducers of growth inhibition and/or differentiation, renin expression did not disappear, indicating that renin expression is associated with a blastic phenotype rather than with cell proliferation.17 Inigo and coworkers analysed 76 samples from patients with AML. Thirty-one patients (41%) were positive for renin gene expression at diagnosis. All renin-positive patients at diagnosis showed no expression during complete remission (CR), but expression recurred in those experiencing relapse and persisted when the disease was refractory to treatment.18 The chimeric protein NUP98-HOXA9, is a prototype of several NUP98 fusions that occur in AML and myelodysplastic syndromes. NUP98-HOXA9 affects the differentiation, proliferation, and gene expression of the primary human CD34+ hematopoietic cells. NUP98-HOXA9 can increase the numbers of erythroid precursors and impaired both myeloid and erythroid
differentiation. Increased renin gene activity was detected during the NUP98-HOXA9 enhanced blast formation. Increased RENIN expression in HL-60 myeloid leukemic cells in our study supports the place of this RAS peptide in the leukemogenesis.

RAS affects numerous biological events that are important for the formation and function of blood cells. Apoptosis, cellular proliferation, intracellular signaling, mobilization, angiogenesis, fibrosis within the cytokine network, and many other essential pathobiological events are affected by the critical RAS molecules. Neoplastic malignant blood cells are derived from the leukemic stem cells within a complex series of pathological proliferative steps. Hematological clonal neoplastic disorders are characterized by the excessive production of malignant cells as well as the disordered apoptosis, impaired differentiation, pathological signaling, and cancer angiogenesis. Inigo and coworkers investigated the effect of captopril, trandolapril and losartan on K562 leukemic cell line and K562 transfected with c-myc, bcl-x and bcl-2 (KmycB, Kbclx and Kbcl2 respectively). ACE inhibitors and losartan inhibited cell growth, decreased c-myc expression and increased apoptosis in their study. Since most of the cellular effects of the local RAS are in an autocrine, paracrine and intracrine fashion, future drugs intended to modulate local RAS functions shall be prepared to have local targeted actions in the tissue microenvironment such as inside BM. Therefore the underlying mechanisms and clinicopathological associations of RAS in myeloid leukemic disorders should be further evaluated not only for academical purposes but also better understanding the biology and future management of the leukemic patients.

REFERENCES


Correspondence
Dr. Burak Uz
Sürsürü Mahallesi, İmam Efendi Bulvarı, Gökkuşağı Sitesi, Hüzzam Apt. Daire: 1
ELAZIĞ / TURKEY

Tel: (+90.506) 429 86 32
e-mail: burakzu78@gmail.com